Breast cancer has been traditionally categorized into four molecular subtypes (luminal A, luminal B, human epidermal growth factor receptor type 2 (HER2) -enriched, and triple-negative) based on the expression of pathological marker proteins such as HER2, estrogen receptor (ER), and progesterone receptor (PR). This evidence concerns the gene ESR1 and breast carcinoma.